The Challenge of Solid Tumor Research
Solid tumors remain one of the most difficult targets in oncology. Unlike hematological cancers, the solid tumor microenvironment presents unique barriers (hypoxia, nutrient depletion, immune suppression) that hinder immune cell infiltration and function. For researchers developing novel therapies, optimizing cell culture conditions is critical to improving cell expansion, survival, and tumor-killing potency.
Why Media Supplements Matter in Solid Tumor Research
Cell culture supplements directly affect cell performance. Variability in serum or undefined supplements can alter proliferation rates, phenotype, and most importantly, tumor cytotoxicity. The published work of Roddy O’Connor et al. (2020) at the University of Pennsylvania (UPENN) Center for Cellular Immunotherapies demonstrated how changing from human serum to Physiologix impacts cytotoxicity, showing that optimizing culture conditions can enhance cell-mediated tumor killing in preclinical models [1].
This reinforces an essential point: your choice of supplement matters.
Introducing Physiologix™ Serum Replacement
Physiologix Serum Replacement was designed to bring consistency and performance to cell culture workflows. Unlike traditional serum, Physiologix is GMP and xeno-free, ensuring reproducible results across experiments and supporting smoother translational pathways from research to the clinic, including for solid tumor research.
Benefits of Physiologix™ Serum Replacement in Solid Tumor Research
- Enhanced Cytotoxic Function: Replacing serum with Physiologix has been shown to improve the tumor killing capability in challenging solid tumor models.
- Consistency Across Experiments: Lot-to-lot reproducibility reduces the risk of variability.
- GMP-Ready: A xeno-free supplement aligns with GMP-friendly workflows, simplifying the transition from discovery to clinical applications.
- Improved Cell Health and Performance: Supports robust proliferation, enhances transduction efficiency, and maintains cell health, viability, and desired phenotypes.
White paper: Physiologix™ Serum Replacement Performance on T Cells
Supporting Tumor-Killing Research
When developing therapies aimed at solid tumors, every experimental parameter can influence the outcome. By selecting a supplement that provides consistent and optimized support for immune cell function, researchers gain an advantage in uncovering real therapeutic potential.
In our paper published with UPENN, we demonstrated how Physiologix can improve the therapeutic potential and in-vivo efficacy of CAR T-cell therapy by promoting a more potent antitumor response. The published data shows anti-GD2 CAR-T cells expanded in OpTmizer™ + 2% Physiologix (Phx) demonstrated significantly superior tumor killing in an in-vivo solid tumor neuroblastoma model when compared to CAR-T cells grown in OpTmizer + 5% human serum (HS). Additionally, quantification of tumor burden in total flux (photons/second) by bioluminescence imaging on days 10 (3×10⁶ CAR-T cell dose) and 14 (0.75×10⁶ CAR-T cell dose) confirmed the improvements seen when Physiologix was supplemented to the media.
Physiologix Serum Replacement is more than just a serum alternative; it’s a tool designed to help researchers overcome the inherent challenges of solid tumor studies and accelerate progress toward effective cancer treatments. Learn more about Physiologix Serum Replacement by visiting our product page.
References
[1] Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, Tu Y, García-Cañaveras JC, Ayari A, Lu Y, Wang A, Rabinowitz JD, Milone MC, June CH, O’Connor RS. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Molecular Therapy Methods & Clinical Development. 2020 Jul 9;18:595-606. doi: 10.1016/j.omtm.2020.07.008. PMID: 32775494; PMCID: PMC7397397.
